about
P185
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialLong-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanomaExosomes in cancer immunotherapy: preclinical data.Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalingsFirst-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.Dendritic cell-based immunotherapy of cancer.Exosome-based immunotherapy.Exosomes for cancer immunotherapy.Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production.Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effectsIsolation and characterization of renal cancer stem cells from patient-derived xenograftsExosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).Cost analysis of adverse events associated with non-small cell lung cancer management in France.Immune-related adverse events with immune checkpoint blockade: a comprehensive review.A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells.Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience.Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience.Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk.Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC.Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.Malignant effusions and immunogenic tumour-derived exosomes.Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.Phase II trial of thalidomide in renal-cell carcinoma.Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Multivirc Group.Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines.A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules.Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma.
P50
Q24801506-EFB49341-04C7-46FD-9F93-379CF1DDE293Q28235082-9DD60818-BF52-4F2C-8D5A-E8B19FCF1F2EQ30668747-92BCC3EB-94BD-4841-9381-9AA82F5D0CE0Q33557623-F204A9FD-4932-4CB4-90F9-95B0E7956191Q33639709-2A38C8D6-57EA-4E5A-96D6-352E6E5EB260Q34082983-24008667-E8EE-48F7-B59B-673CF15FE932Q35630835-162FE7B4-5EB2-447D-8682-A9B2F7F6C1FDQ35914665-C172BEF1-62EA-4CAD-9F10-322581E7B563Q36369610-74D0550E-AFF6-4992-9393-4BCA654549D1Q36985600-CB6A0D8C-C311-497E-9EA4-48A7D0AB1AA1Q37085808-514DABDE-1CBF-48A8-81A1-3CDA46FFC6BBQ38345028-B10D550D-D148-46A1-B509-21962C8E5D9AQ38616101-D74E3188-E3BC-4078-987F-26D9D7433994Q38631475-74B620C5-F6BF-4140-A7DD-9D46362EE86DQ38696141-66B4E0AB-1571-473B-92C6-2EE370721975Q39021494-C0416718-8F9A-461A-9601-80E8E9DA33D5Q39470265-8A6ED249-8FE5-4F47-B3AB-DE95D9F54EA4Q39692550-52BB5849-17AF-48AD-8F27-B4CFD3EE9129Q39846121-FAE02197-5759-4D8A-8B26-439B1FD7918FQ40233559-F70D28E2-5930-409A-ADEE-2522BAFE6E9BQ40539792-54D43F09-9019-4031-8DDF-B991E84754C7Q40592158-FF91F272-C096-4F7A-8936-9E60EA877F13Q40634671-90631A8B-3339-4936-9288-85E43ECCF4EDQ40680760-5F691F64-1A87-46A9-A697-282E95BF173CQ40737994-87A01B06-1D17-4AAD-BEF8-461FE171782AQ41598282-438973C7-E6A1-42A7-9AB9-A063E70CF5BAQ43073122-182EE044-D70A-4F77-B281-BB1917878F46Q43922483-CBF70B9F-34F4-43D5-AD90-AE7D9DE7C7F4Q44082514-992BF2D0-3771-4987-B888-79ADCFE20563Q44100364-1BD913E3-DA66-4C35-A771-3B698DC7373DQ44101920-AECC4605-99F2-4D01-8ED5-1FE49D7A1B60Q44902045-97EDD315-9E06-4F89-B2C2-1BBCEF25F76BQ45143413-664CBE7B-5135-4401-873B-B796DE663D20Q45152595-2457D7DA-045E-4E8A-80DC-19DD157EC6D7Q45754354-917AF6C7-484F-41B3-9DC4-610486974776Q46902752-230B6D1B-23E8-4712-9507-11A2E2B468FBQ47306783-2DDF86A1-56A0-48D5-BFF9-BFD07C5CBC7FQ47396230-F4464A06-ECA4-4E58-870E-91F0C5CA0DEBQ47644573-596997A2-665C-4164-B526-1821FC63A468Q47937100-0BE5633B-77CC-46C0-836A-C937CB976ED8
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Eric Angevin
@en
Eric Angevin
@es
Eric Angevin
@nl
Éric Angevin
@fr
Éric Angevin
@sl
type
label
Eric Angevin
@en
Eric Angevin
@es
Eric Angevin
@nl
Éric Angevin
@fr
Éric Angevin
@sl
prefLabel
Eric Angevin
@en
Eric Angevin
@es
Eric Angevin
@nl
Éric Angevin
@fr
Éric Angevin
@sl
P214
P268
P269
P106
P1153
7003796212
P184
P21
P213
0000 0000 0227 8525
P214
P268
P269
P31
P496
0000-0001-6249-7209
P569
1950-01-01T00:00:00Z
P6634
eric-angevin-16871b96
P735
P7859
viaf-56936732